BioSpace News Archive

Biotech Bay

Glaucoma Innovations to be Presented at 13th Annual New Horizons Forum in San Francisco

Glaucoma Research Foundation (GRF) will host the 13th Annual Glaucoma 360 New Horizons Forum on February 9th at San Francisco’s historic Westin St. Francis Hotel.

January 16, 2024
·
2 min read
Business

Vaxcyte Appoints Whitney Jones as Chief People Officer

Vaxcyte, Inc. today announced the appointment of Whitney Jones as Chief People Officer.

January 16, 2024
·
6 min read
Business

Omnicell to Release Fourth Quarter and Full Year 2023 Financial Results on February 8, 2024

Omnicell to Release Fourth Quarter and Full Year 2023 Financial Results on February 8, 2024.

January 16, 2024
·
1 min read
Deals

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - January 16, 2024

TransMedics Group, Inc. today announced that on January 12, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 24,535 shares.

January 16, 2024
·
2 min read
Pharm Country

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

Cellectis announced that it has drawn down the second tranche of €15 million under the credit facility agreement for up to €40 million entered into with the European Investment Bank on December 28, 2022.

January 16, 2024
·
4 min read
Biotech Beach

Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced data from its presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco.

January 16, 2024
·
6 min read
Business

Arvinas Appoints Jared Freedberg as General Counsel

Arvinas, Inc. announced that Jared Freedberg, J.D., has joined the company as General Counsel.

January 16, 2024
·
5 min read
Drug Development

MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024

MEI Pharma, Inc. (Nasdaq: MEIP) today announced the design of the ongoing Phase 1b study of the mitochondrial oxidative phosphorylation (OXPHOS) inhibitor ME-344 in combination with bevacizumab (Avastin®) in refractory metastatic colorectal cancer patients will be presented during a poster session at the 2024 ASCO Gastrointestinal Cancers Symposium to be held January 18 – 20, 2024.

January 16, 2024
·
7 min read
Business

Biomerica Reports Second Quarter 2024 Financial Results

Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2024 ended November 30, 2023.

January 16, 2024
·
5 min read
Lone Star Bio

Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces that it is expanding its pipeline in neurodegenerative conditions for COYA 302 beyond ALS to include frontotemporal dementia (FTD) and Parkinson’s disease (PD).

January 16, 2024
·
13 min read